Oral Therapies in Psoriasis & Melasma: From Evidence to Emerging Opportunities

Abstract

Psoriasis and melasma are two distinct dermatological conditions with significant impact on patient quality of life, each requiring nuanced therapeutic approaches. This comprehensive review critically examines the evolving landscape of oral therapies for both diseases, highlighting established agents, underlying pathophysiology, recent advances, and emerging opportunities. Emphasis is placed on clinical efficacy, safety profiles, mechanism-based strategies, and practical implementation for healthcare professionals, with a focus on integrating evidence-based recommendations and the latest guideline updates.

Introduction

Psoriasis and melasma, though fundamentally different in etiology and clinical course, represent common disorders seen in dermatological practice worldwide. Psoriasis is a chronic, immune-mediated inflammatory disease, while melasma is a pigmentary disorder often exacerbated by hormonal and environmental factors. Both conditions can lead to significant psychosocial distress. As topical therapies and phototherapy often present limitations in moderate-to-severe cases, oral systemic treatments have become essential in the management paradigm. This article reviews current oral therapies, explores novel agents, and offers practical, evidence-based insights for clinicians.

Epidemiology / Disease Burden

Psoriasis affects approximately 2–3% of the global population, with notable regional variation. Its prevalence is higher in Western countries and is associated with considerable morbidity due to comorbidities such as psoriatic arthritis, cardiovascular disease, and metabolic syndrome. Conversely, melasma predominantly affects women of reproductive age, particularly those with Fitzpatrick skin types III–V, and is more prevalent in regions with higher ultraviolet exposure. The chronicity and relapsing nature of both conditions present a substantial burden, both in healthcare resource utilization and patient-reported outcomes, including quality of life and psychological well-being.

Pathophysiology

Psoriasis is characterized by a complex interplay of genetic predisposition, immune dysregulation, and environmental triggers. The central role of T-helper 17 cells and the interleukin-23/IL-17 axis has been well established, resulting in keratinocyte hyperproliferation and chronic inflammation. In contrast, melasma is driven by multifactorial mechanisms, including UV-induced upregulation of melanogenesis, hormonal influences, and genetic susceptibility. Emerging evidence implicates the role of cutaneous inflammation, oxidative stress, and even vascular factors in melasma pathogenesis, prompting a re-evaluation of therapeutic targets.

Risk Factors

Risk factors for psoriasis include family history, obesity, smoking, alcohol intake, and certain medications (e.g., lithium, beta-blockers). For melasma, risk is heightened by female gender, pregnancy, use of oral contraceptives, hormone replacement therapy, and chronic sun exposure. Recent studies suggest that psychological stress and metabolic syndrome may exacerbate both conditions, highlighting the importance of comprehensive risk assessment in clinical practice.

Clinical Features

Psoriasis presents with erythematous, scaly plaques most commonly on extensor surfaces, scalp, and lumbosacral region. Nail changes and joint involvement may also occur. Disease severity is typically assessed using the Psoriasis Area and Severity Index (PASI). Melasma manifests as symmetric, hyperpigmented macules and patches, usually on the face, with patterns classified as centrofacial, malar, or mandibular. Both disorders can have significant psychosocial ramifications, necessitating a holistic patient-centered approach.

Diagnosis

Diagnosis of psoriasis is primarily clinical, supported by histopathology in atypical cases. Dermoscopy may assist in differentiating from other papulosquamous disorders. Laboratory workup may be indicated to assess comorbidities or monitor systemic therapy. Melasma is diagnosed clinically, with Wood\'s lamp examination and dermoscopy aiding in depth assessment. Biopsy is rarely required but may be considered in refractory or atypical cases. Tools such as the Melasma Area and Severity Index (MASI) are useful for grading severity and monitoring response to therapy.

Treatment & Management

Oral therapies for psoriasis include traditional systemic agents such as methotrexate, cyclosporine, and acitretin. Methotrexate, an antimetabolite, is effective in moderate-to-severe disease but requires careful monitoring for hepatotoxicity and bone marrow suppression. Cyclosporine offers rapid disease control but is limited by nephrotoxicity and hypertension. Acitretin, a retinoid, is useful for pustular and erythrodermic variants. Apremilast, a phosphodiesterase-4 inhibitor, offers an oral, non-immunosuppressive alternative with a favorable safety profile, albeit with modest efficacy. Melasma management relies on sun protection and topical agents as first-line therapy; however, oral tranexamic acid has emerged as an effective adjunct, inhibiting plasminogen activation and melanogenesis. Other oral agents under evaluation include antioxidants and hormonal modulators, though evidence remains limited.

Recent Advances / Emerging Therapies

The landscape of oral therapies in psoriasis has expanded with the advent of small molecule inhibitors targeting specific immune pathways. Janus kinase (JAK) inhibitors, such as tofacitinib and deucravacitinib (a TYK2 inhibitor), have demonstrated efficacy in clinical trials, offering new options for patients inadequately controlled with traditional agents. Safety concerns, particularly with long-term use, necessitate vigilant monitoring. In melasma, ongoing research is evaluating oral agents that modulate oxidative stress, vascular factors, and neurohormonal pathways. Oral glutathione, polypodium leucotomos extract, and even metformin have shown preliminary promise in small studies, though robust data are still forthcoming.

Guideline Recommendations

Current psoriasis management guidelines (e.g., AAD, EADV) recommend individualized therapy based on disease severity, comorbidities, and patient preference. Methotrexate remains a mainstay for moderate-to-severe cases, while apremilast is positioned as a second-line option. Biologics are preferred when oral agents are contraindicated or ineffective. For melasma, guidelines endorse oral tranexamic acid as an adjunct in recalcitrant cases, with careful assessment of contraindications and risk of thromboembolic events. Long-term oral therapies require periodic evaluation for adverse effects and therapeutic response, underscoring the need for shared decision-making and patient education.

Conclusion

Oral therapies represent a cornerstone in the management of moderate-to-severe psoriasis and challenging melasma. Advances in understanding disease mechanisms have catalyzed the development of targeted agents with improved efficacy and safety profiles. While traditional systemic drugs remain valuable, emerging oral therapies hold promise for optimizing patient outcomes. Ongoing research and guideline updates will further refine therapeutic algorithms, emphasizing the importance of individualized, evidence-based care by healthcare professionals.